Monitoring therapeutic drugs

Therapeutic Drug Monitoring and Toxicology by Liquid Chromatography, edited by Steven H. Y. Wong... [Pg.431]

TABLE 5-5. Therapeutic Drug Monitoring for Adverse Effects of Pharmacotherapy for Acute Coronary Syndromes... [Pg.103]

Develop a therapeutic drug-monitoring plan to assess both the effectiveness and the adverse... [Pg.829]

The most commonly used corticosteroids are methylpred-nisolone (IV and oral) and prednisone (oral), although prednisolone and dexamethasone also have been shown to be effective for organ transplantation. Corticosteroid doses vary by center-specific protocols, organ type, and patient characteristics. A typical taper would include an IV 100 to 500 mg bolus of methylprednisolone at the time of transplant and then a taper over 5 to 7 days to a maintenance dose of prednisone 20 mg/day or complete cessation.2,7 It is important for practitioners to know that approximately 4 mg methylprednisolone is equivalent to 5 mg prednisone and 0.75 mg dexamethasone.11 At most transplant centers, therapeutic drug monitoring of corticosteroids is not employed. Corticosteroids are associated with a variety of acute and chronic toxicides. The most common adverse events have been summarized in Table 52-5. [Pg.842]

Select patients for whom therapeutic drug monitoring may be valuable. [Pg.1105]

Therapeutic drug monitoring (TDM) or applied pharmacokinetics is the use of serum drug concentrations to optimize therapy.28,36,37 Non-AIDS patients with drug-susceptible TB... [Pg.1115]

Based on the information provided, which clinical and laboratory parameters should be monitored in this patient to determine efficacy and avoid toxicity Is this patient a can-didate for therapeutic drug monitoring Why or why not ... [Pg.1115]

Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002 62 2169-2183. [Pg.1116]

Therapeutic drug monitoring The process of using drug concentrations, pharmacokinetic principles, and pharmacodynamic criteria to optimize drug therapy in individual patients. [Pg.1578]

M Mayersohn. Special pharmacokinetic considerations in the elderly. In WE Evans, JJ Schentag, WJ Jusko, eds. Applied Pharmacokinetics Principles of Therapeutic Drug Monitoring. 3rd ed. Vancouver, WA Applied Therapeutics, 1992, pp. 9-1-9-43. [Pg.76]

Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine evidence from a therapeutic drug monitoring service. [Pg.377]

Levomepromazine Direct immersion PDMS (100) GC-NPD (LOQ 5 ng/mL) Application to therapeutic drug monitoring Kruggel and Ulrich, 2000(18)... [Pg.55]

Niederlander H.A.G. et al., 2006. High throughtput therapeutic drug monitoring of clozapine and metabolites in serum by online coupling of solid phase extraction with liquid chromatography-mass spectrometry. J Chromatogr B 834 98. [Pg.296]

Applications of High-Throughput Analysis in Therapeutic Drug Monitoring... [Pg.299]

See also in sourсe #XX -- [ Pg.514 ]

See also in sourсe #XX -- [ Pg.300 , Pg.301 , Pg.302 , Pg.303 , Pg.304 , Pg.305 , Pg.306 , Pg.307 , Pg.308 , Pg.309 , Pg.310 , Pg.311 , Pg.312 , Pg.313 , Pg.314 ]

See also in sourсe #XX -- [ Pg.13 ]

See also in sourсe #XX -- [ Pg.81 ]

See also in sourсe #XX -- [ Pg.68 , Pg.110 , Pg.112 , Pg.120 , Pg.121 , Pg.127 , Pg.128 , Pg.129 , Pg.130 , Pg.131 , Pg.132 , Pg.133 , Pg.134 , Pg.135 , Pg.136 , Pg.137 , Pg.145 , Pg.185 ]

See also in sourсe #XX -- [ Pg.60 , Pg.61 , Pg.62 ]

See also in sourсe #XX -- [ Pg.252 ]

See also in sourсe #XX -- [ Pg.108 , Pg.109 ]

See also in sourсe #XX -- [ Pg.586 , Pg.2630 , Pg.2636 , Pg.3027 , Pg.3034 ]

See also in sourсe #XX -- [ Pg.458 ]

See also in sourсe #XX -- [ Pg.61 ]

See also in sourсe #XX -- [ Pg.156 ]

See also in sourсe #XX -- [ Pg.229 ]

See also in sourсe #XX -- [ Pg.326 ]

See also in sourсe #XX -- [ Pg.405 ]

See also in sourсe #XX -- [ Pg.18 , Pg.264 , Pg.560 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...